d-propranolol protects against oxidative stress and progressive cardiac dysfunction in iron overloaded rats

Canadian Journal of Physiology and Pharmacology

Volumn 90, Issue 9, 2012, Pages 1257-1268

  Kramer, Jay H ^a   Spurney, Christopher F ^b   Iantorno, Micaela ^b   Tziros, Constantine ^a   Chmielinska, Joanna J ^a   Mak, I Tong ^a   Weglicki, William B ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Cardiac dysfunction; D propranolol; Echocardiography; Iron overload; Oxidative stress

Indexed keywords

8 ISOPROSTANE; BETA N ACETYLGALACTOSAMINIDASE; GLUTATHIONE; IRON DEXTRAN; PROPRANOLOL; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA PRESSURE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ERYTHROCYTE; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE PRESSURE; HEART OUTPUT; HEART PERFUSION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; IRON OVERLOAD; MALE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ACETYLGLUCOSAMINIDASE; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARDIAC OUTPUT; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; ERYTHROCYTES; GLUTATHIONE; HEART DISEASES; IRON OVERLOAD; MALE; MYOCARDIUM; NEUTROPHILS; OXIDATIVE STRESS; PERFUSION; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; SUPEROXIDE DISMUTASE; TREATMENT OUTCOME;

EID: 84865435244     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y2012-091     Document Type: Article

References (51)

1. Bacon, B.R., Tavill, A.S., Brittenham, G.M., Park, C.H., and Recknagel, R.O. 1983. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. J. Clin. Invest. 71(3): 429-439. doi:10. 1172/JCI110787. PMID:6826715.
2. Bartfay, W.J., Hou, D., Brittenham, G.M., Bartfay, E., Sole, M.J., Lehotay, D., and Liu, P.P. 1998. The synergistic effects of vitamin E and selenium in iron-overloaded mouse hearts. Can. J. Cardiol. 14(7): 937-941. PMID:9706279.
3. Berenshtein, E., Vaisman, B., Goldberg-Langerman, C., Kitrossky, N., Konijn, A.M., and Chevion, M. 2002. Roles of ferritin and iron in ischemic preconditioning of the heart. Mol. Cell. Biochem. 234-235(1): 283-292. doi:10.1023/A:1015923202082. PMID: 12162445.
4. Cramb, G. 1986. Selective lysosomal uptake and accumulation of the beta-adrenergic antagonist propranolol in cultured and isolated cell systems. Biochem. Pharmacol. 35(8): 1365-1372. doi:10.1016/ 0006-2952(86)90283-2. PMID:3008762.
5. Delea, T.E., Edelsberg, J., Sofrygin, O., Thomas, S.K., Baladi, J.-F., Phatak, P.D., and Coates, T.D. 2007. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion, 47(10): 1919-1929. doi:10.1111/j.1537-2995.2007.01416.x. PMID:17880620.
6. Dickens, B.F., Weglicki, W.B., Boehme, P.A., and Mak, I.T. 2002. Antioxidant and lysosomotropic properties of acridine proprano-lol: protection against oxidative endothelial cell injury. J. Mol. Cell. Cardiol. 34(2): 129-137. doi:10.1006/jmcc.2001.1495. PMID:11851353.
7. Eaton, J.W., and Qian, M. 2002. Molecular bases of cellular iron toxicity. Free Radic. Biol. Med. 32(9): 833-840. doi:10.1016/ S0891-5849(02)00772-4. PMID:11978485.
8. Folden, D.V., Gupta, A., Sharma, A.C., Li, S.Y., Saari, J.T., and Ren, J. 2003. Malondialdehyde inhibits cardiac contractile function in ventricular myocytes via a p38 mitogen-activated protein kinase-dependent mechanism. Br. J. Pharmacol. 139(7): 1310-1316. doi:10.1038/sj.bjp.0705384. PMID:12890710.
9. Giardina, P.J., and Grady, R.W. 1995. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Semin. Hematol. 32(4): 304-312. PMID:8560288.
10. Gujja, P., Rosing, D.R., Tripodi, D.J., and Shizukuda, Y. 2010. Iron overload cardiomyopathy: better understanding of an increasing disorder. J. Am. Coll. Cardiol. 56(13): 1001-1012. doi:10.1016/j. jacc.2010.03.083. PMID:20846597.
11. Gunther, T., Hollriegl, V., Vormann, J., Disch, G., and Classen, H.G. 1992. Effects of Fe loading on vitamin E and malondialdehyde of liver, heart and kidney from rats fed diets containing various amounts of magnesium and vitamin E. Magnesium-Bulletin, 14 (3): 88-93. Haug, Heidelberg, Germany.
12. Halliwell, B., and Gutteridge, J.M.C. 1986. Oxygen free radicals and iron in relation to biology and medicine: Some problems and concepts. Arch. Biochem. Biophys. 246(2): 501-514. doi:10.1016/ 0003-9861(86)90305-X. PMID:3010861.
13. Hershko, C., Link, G., and Cabantchik, I. 1998. Pathophysiology of iron overload. Ann. N. Y. Acad. Sci. 850: 191-201. doi:10.1111/j. 1749-6632.1998.tb10475.x. PMID:9668540.
14. Horackova, M., Ponka, P., and Byczko, Z. 2000. The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H(2)O(2) injury in adult cardiomyocytes. Cardiovasc. Res. 47(3): 529-536. doi:10.1016/ S0008-6363(00)00088-2. PMID:10963725.
15. Jensen, P.D., Olsen, N., Bagger, J.P., Jensen, F.T., Christensen, T., and Ellegaard, J. 1997. Cardiac function during iron chelation therapy in adult non- thalassaemic patients with transfusional iron overload. Eur. J. Haematol. 59(4): 221-230. doi:10.1111/j.1600-0609.1997.tb00981.x. PMID:9338620.
16. Kadiiska, M.B., Burkitt, M.J., Xiang, Q.H., and Mason, R.P. 1995. Iron supplementation generates hydroxyl radical in vivo. An ESR spin-trapping investigation. J. Clin. Invest. 96(3): 1653-1657. doi:10.1172/JCI118205. PMID:7657835.
17. Komarov, A.M., Hall, J.M., Chmielinska, J.J., and Weglicki, W.B. 2006. Iron uptake and release by macrophages is sensitive to propranolol. Mol. Cell. Biochem. 288(1-2): 213-217. doi:10. 1007/s11010-006-9138-2. PMID:16718379.
18. Kontoghiorghes, G.J. 1995. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other Fe and aluminium chelating drugs. Toxicol. Lett. 80(1-3): 1-18. doi:10.1016/0378-4274 (95)03415-H. PMID:7482575.
19. Kramer, J.H., Mak, I.T., Freedman, A.M., and Weglicki, W.B. 1991. Propranolol reduces anoxia/reoxygenation-mediated injury of adult myocytes through an anti-radical mechanism. J. Mol. Cell. Cardiol. 23(11): 1231-1244. doi:10.1016/0022-2828(91)90081-V. PMID:1687065.
20. Kramer, J.H., Misik, V., and Weglicki, W.B. 1994. Lipid peroxidation-derived free radical production and post-ischemic myocardial reperfusion injury. Ann. N. Y. Acad. Sci. 723: 180-196. doi:10. 1111/j.1749-6632.1994.tb36725.x. PMID:8030864.
21. Kramer, J.H., Lightfoot, F., and Weglicki, W.B. 2000. Cardiac tissue iron: effects on postischemic function and free radical production, and its possible role during preconditioning. Cell. Mol. Biol. 46(8): 1313-1327. PMID:11156477.
22. Kramer, J.H., Murthi, S.B., Wise, R.M., Mak, I.T., and Weglicki, W. B. 2006. Antioxidant and lysosomotropic properties of acute d-propranolol underlies its cardioprotection of postischemic hearts from moderate iron-overloaded rats. Exp. Biol. Med. 231(4): 473-484. PMID:16565443.
23. Kramer, J.H., Spurney, C., Iantorno, M., Tziros, C., Mak, I.-T., Tejero-Taldo, M.I., et al. 2009. Neurogenic inflammation and cardiac dysfunction due to hypomagnesemia. Am. J. Med. Sci. 338 (1): 22-27. doi:10.1097/MAJ.0b013e3181aaee4d. PMID: 19593099.
24. Kramer, J.H., Spurney, C.F., Iantorno, M., Tziros, C., Mak, I.T., and Weglicki, W.B. 2009a. D-propranolol protects against oxidative stress and progressive cardiac dysfunction in Fe-overloaded rats. J. Mol. Cell. Cardiol. 46(5 Suppl. 1): S25.
25. Kremastinos, D.T., Tiniakos, G., Theodorakis, G.N., Katritsis, D.G., and Toutouzas, P.K. 1995. Myocarditis in beta-thalassemia major. A cause of heart failure. Circulation, 91(1): 66-71. PMID:7805220.
26. Lombardo, T., Tamburino, C., Bartoloni, G., Morrone, M.L., Frontini, V., Italia, F., et al. 1995. Cardiac iron overload in thalassemic patients: an endomyocardial biopsy study. Ann. Hematol. 71(3): 135-141. doi:10.1007/BF01702649. PMID: 7548332.
27. Luna, L.G. 1968. Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology. 3rd ed. pp. 184-185.
28. Mak, I.T., and Weglicki, W.B. 1988. Protection by b-blocking agents against free radical -mediated sacrolemmal lipid peroxidation. Circ. Res. 63(1): 262-266. PMID:2898307.
29. Mak, I.T., and Weglicki, W.B. 1992. Membrane antiperoxidative activities of D-propranolol, L-propranolol and dimethyl quaternary propranolol (UM-272). Pharmacol. Res. 25(1): 25-30. doi:10. 1016/S1043-6618(05)80061-1. PMID:1738755.
30. Mak, I.T., and Weglicki, W.B. 1994. Antioxidant activity of calcium channel blocking drugs. Methods Enzymol. 234: 620-630. PMID: 7808338.
31. Mak, I.T., Misra, H.P., and Weglicki, W.B. 1983. Temporal relationship of free radical-induced lipid peroxidation and loss of latent enzyme activity in highly enriched hepatic lysosomes. J. Biol. Chem. 258(22): 13733-13737. PMID:6643449.
32. Mak, I.T., Arroyo, C.M., and Weglicki, W.B. 1989. Inhibition of sarcolemmal carbon-centered free radical formation by proprano-lol. Circ. Res. 65(4): 1151-1156. PMID:2551530.
33. Mak, I.T., Komarov, A.M., Wagner, T.L., Stafford, R.E., Dickens, B.F., and Weglicki, W.B. 1996. Enhanced NO production during Mg deficiency and its role in mediating red blood cell glutathione loss. Am. J. Physiol. Cell Physiol. 271(1): C385-C390. PMID: 8760069.
34. Mak, I.T., Chmielinska, J.J., Nedelec, L., Torres, A., and Weglicki, W.B. 2006. D-Propranolol attenuates lysosomal iron accumulation and oxidative injury in endothelial cells. J. Pharmacol. Exp. Ther. 317(2): 522-528. doi:10.1124/jpet.105.097709. PMID:16456084.
35. Mak, I.T., Kramer, J.H., Chmielinska, J.J., Khalid, H., Landgraf, K., and Weglicki, W.B. 2008. Inhibition of neutral endopeptidase potentiates neutrophil activation during Mg-deficiency in the rat. Inflamm. Res. 57(7): 300-305. doi:10.1007/s00011-007-7186-z. PMID:18607539.
36. Mak, I.T., Chmielinska, J.J., Kramer, J.H., and Weglicki, W.B. 2009. AZT-induced oxidative cardiovascular toxicity-attenuation by Mg-supplementation. Cardiovasc. Toxicol. 9(2): 78-85. doi:10. 1007/s12012-009-9040-8. PMID:19484392.
37. Mariotti, E., Angelucci, E., Agostini, A., Baronciani, D., Sgarbi, E., and Lucarelli, G. 1998. Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. Br. J. Haematol. 103(4): 916-921. doi:10.1046/j.1365-2141.1998.01099.x. PMID:9886301.
38. Masini, A., Trenti, T., Ceccarelli, D., and Muscatello, U. 1986. Mitochondrial involvement in causing cell injury in experimental hepatic iron overload. Ann. N. Y. Acad. Sci. 488: 517-519. doi:10. 1111/j.1749-6632.1986.tb46587.x.
39. Moon, S.N., Han, J.W., Hwang, H.S., Kim, M.J., Lee, S.J., Lee, J.Y., et al. 2011. Establishment of secondary iron overloaded mouse model: evaluation of cardiac function and analysis according to iron concentration. Pediatr. Cardiol. 32(7): 947-952. doi:10.1007/ s00246-011-0019-4. PMID:21656238.
40. Murphy, C.J., and Oudit, G.Y. 2010. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J. Card. Fail. 16(11): 888-900. doi:10.1016/j.cardfail.2010.05.009. PMID:21055653.
41. Nakaya, H., Tohse, N., and Kanno, M. 1987. Electrophysiological derangements induced by lipid peroxidation in cardiac tissue. Am. J. Physiol. 253(5): H1089-H1097. PMID:3688253.
42. Oudit, G.Y., Trivieri, M.G., Khaper, N., Husain, T., Wilson, G.J., Liu, P., et al. 2004. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model. Circulation, 109(15): 1877-1885. doi:10.1161/01.CIR. 0000124229.40424.80. PMID:15037530.
43. Pepper, J.R., Mumby, S., and Gutteridge, J.M. 1995. Blood cardioplegia increases plasma iron overload and thiol levels during cardiopulmonary bypass. Ann. Thorac. Surg. 60(6): 1735-1740. doi:10.1016/0003-4975(95)00896-9. PMID:8787472.
44. Politi, A., Sticca, M., and Galli, M. 1995. Reversal of haemochro-matotic cardiomyopathy in beta thalassaemia by chelation therapy. Br. Heart J. 73(5): 486-487. doi:10.1136/hrt.73.5.486. PMID: 7786668.
45. Schwartz, K.A., Li, Z., Schwartz, D.E., Cooper, T.G., and Braselton, W.E. 2002. Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction. J. Appl. Physiol. 93(2): 746-751. PMID:12133887.
46. Taher, A., and Cappellini, M.D. 2009. Update on the use of deferosirox in the management of iron overload. Ther. Clin. Risk Manag. 5: 857-868. doi:10.2147/TCRM.S5497. PMID:19898650.
47. 2+ channel modifiers: possible implications in iron overload. Circ. Res. 84(11): 1302-1309. PMID:10364568.
48. van der Kraaij, A.M.M., Mostert, L., van Eijk, H.G., and Koster, J.F. 1988. Iron-load increases the susceptibility of rat hearts to oxygen reperfusion damage. Protection by the antioxidant (+)-cyanidanol-3 and deferoxamine. Circulation, 78(2): 442-449. doi:10.1161/01. CIR.78.2.442. PMID:3396180.
49. Vichinsky, E. 2008. Oral iron chelators and the treatment of iron overload in pediatric patients with chronic anemia. Pediatrics, 121(6): 1253-1256. doi:10.1542/peds.2007-1824. PMID:18519495.
50. Voogd, A., Sluiter, W., van Eijk, H.G., and Koster, J.F. 1992. Low molecular weight iron and the oxygen paradox in isolated rat hearts. J. Clin. Invest. 90(5): 2050-2055. doi:10.1172/JCI116086. PMID:1430227.
51. Whittaker, P., Wamer, W.G., Chanderbhan, R.F., and Dunkel, V.C. 1996. Effects of alpha-tocopherol and beta-carotene on hepatic lipid peroxidation and blood lipids in rats with dietary iron overload. Nutr. Cancer, 25(2): 119-128. doi:10.1080/ 01635589609514434. PMID:8710681.